Gemini Therapeutics, Inc. (GMTX): Price and Financial Metrics

Gemini Therapeutics, Inc. (GMTX): $1.26

0.04 (+3.28%)

POWR Rating

Component Grades













Add GMTX to Watchlist
Sign Up

Industry: Biotech



in industry

GMTX Stock Price Chart Interactive Chart >

Price chart for GMTX

GMTX Price/Volume Stats

Current price $1.26 52-week high $12.95
Prev. close $1.22 52-week low $1.16
Day low $1.23 Volume 66,500
Day high $1.29 Avg. volume 259,891
50-day MA $1.46 Dividend yield N/A
200-day MA $2.61 Market Cap 54.47M

Gemini Therapeutics, Inc. (GMTX) Company Bio

Gemini Therapeutics, Inc. operates as a precision medicine company. The Company focuses on dry macular degeneration which is a disease comprised of numerous genetic variants. Gemini Therapeutics serves customers worldwide.

GMTX Latest News Stream

Event/Time News Detail
Loading, please wait...

GMTX Latest Social Stream

Loading social stream, please wait...

View Full GMTX Social Stream

Latest GMTX News From Around the Web

Below are the latest news stories about Gemini Therapeutics Inc that investors may wish to consider to help them evaluate GMTX as an investment opportunity.

Gemini Therapeutics Provides GEM103 Program Update

CAMBRIDGE, Mass., January 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103’s clinical development program.

Yahoo | January 10, 2022

Gemini Therapeutics (NASDAQ:GMTX) Given New $15.00 Price Target at SVB Leerink

Gemini Therapeutics (NASDAQ:GMTX) had its price target reduced by SVB Leerink from $25.00 to $15.00 in a report released on Monday, reports. SVB Leerink currently has an outperform rating on the stock. A number of other research analysts also recently commented on the stock. The Goldman Sachs Group cut their target price on shares []

Transcript Daily | December 24, 2021

Gemini Therapeutics, Inc. (NASDAQ:GMTX) Receives Average Recommendation of Buy from Brokerages

Shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX) have been given an average recommendation of Buy by the six brokerages that are presently covering the company, reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokerages []

Dakota Financial News | December 22, 2021

Gemini Therapeutics (NASDAQ:GMTX) Rating Lowered to Hold at Zacks Investment Research

Gemini Therapeutics (NASDAQ:GMTX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report issued on Friday, reports. According to Zacks, Gemini Therapeutics Inc. is a clinical stage precision medicine company. It engages in developing novel therapeutic compounds to treat genetically defined age-related macular degeneration. The companys lead [] The post Gemini Therapeutics (NASDAQ:GMTX) Rating Lowered to Hold at Zacks Investment Research appeared first on ETF Daily News .

ETF Daily News | December 19, 2021

H.C. Wainwright Thinks Gemini Therapeutics’ Stock is Going to Recover

H.C. Wainwright analyst Matthew Caufield initiated coverage with a Buy rating on Gemini Therapeutics (GMTX – Research Report) today and set a price target of $20.00. The company's shares closed last Tuesday at $2.43, close to its 52-week low of $2.28. According to, Caufield is ranked #4051 out of 7739 analysts. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gemini Therapeutics with a $22.50 average price target. See the top stocks recommended by analysts >> The company has a one-year high of $19.09 and a one-year low of $2.28. Currently, Gemini Therapeutics has an average volume of 120.5K.

Brian Anderson on TipRanks | December 15, 2021

Read More 'GMTX' Stories Here

GMTX Price Returns

1-mo -19.23%
3-mo -11.89%
6-mo -54.35%
1-year -89.76%
3-year N/A
5-year N/A
YTD -56.70%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5971 seconds.